

Cancer Vaccines: Approach for Cancer Treatment

Jessica John^{*}

Department of Immunology, University of Toronto, Toronto, Canada

DESCRIPTION

Cancer is one of the leading causes of death worldwide, and while several treatment options are available, they often effect with severe side effects. Therefore, there is a need for more effective and less harmful cancer treatments [1-3]. Cancer vaccines are emerging as a promising approach for cancer treatment.

Types of cancer vaccines

There are two types of cancer vaccines, preventive and therapeutic. Preventive cancer vaccines aim to prevent cancer by targeting viruses that can cause cancer, such as the Human Papilloma Virus (HPV). On the other hand, therapeutic cancer vaccines aim to treat existing cancer by stimulating the immune system to attack cancer cells.

Mechanism of cancer vaccines

Cancer vaccines work by training the immune system to recognize and attack cancer cells. The vaccines contain specific antigens present on cancer cells, which are recognized by the immune system as foreign. The immune system then produces antibodies against these antigens, which attack cancer cells. Cancer vaccines also boost the activity of immune cells, such as T-cells, which are responsible for killing cancer cells [4].

Challenges in developing cancer vaccines: Developing cancer vaccines is challenging due to the complexity of cancer cells and the ability of cancer cells to evade the immune system. Cancer cells can also mutate rapidly, making it difficult to develop vaccines that can target all cancer cells. Additionally, cancer vaccines may not be effective in patients with weakened immune systems.

Current status of cancer vaccines: Several cancer vaccines are in various stages of development and clinical trials. For example, the HPV vaccine has been shown to be highly effective in preventing cervical cancer caused by HPV. Therapeutic cancer vaccines, such as sipuleucel-T, have been approved for the treatment of prostate cancer. Other cancer vaccines, such as

those targeting melanoma and lung cancer, are in clinical trials and showing promising results [5-7].

Effectiveness of cancer vaccines: Cancer vaccines work by training the immune system to recognize and attack cancer cells. While the effectiveness of cancer vaccines may vary depending on the type of cancer and the patient's immune system, studies have shown that cancer vaccines can be effective in treating certain types of cancer [8]. For example, sipuleucel-T, a therapeutic cancer vaccine, has been approved for the treatment of prostate cancer and has been shown to increase survival rates in patients with advanced prostate cancer.

Limitations of cancer vaccines

While cancer vaccines show promise as a treatment option for cancer, there are limitations to their effectiveness. Developing cancer vaccines that can target all cancer cells is challenging, and cancer cells can mutate rapidly, making it difficult to develop vaccines that can keep up with the mutation. Additionally, cancer vaccines may not be effective in patients with weakened immune systems.

Combination therapy

To overcome the limitations of cancer vaccines, combination therapy is often used. Combination therapy involves using cancer vaccines in combination with other cancer treatments, such as chemotherapy or radiation therapy, to increase the effectiveness of cancer treatment[9,10]. Combination therapy has shown promising results in clinical trials, and on-going research is being conducted to optimize the use of cancer vaccines in combination therapy.

CONCLUSION

Cancer vaccines are a promising approach for cancer treatment, with the potential to offer a less harmful and more effective treatment option for cancer patients. While there are challenges in developing cancer vaccines, the progress made so far is encouraging. With further research and development, cancer vaccines may become a standard treatment option for cancer in the future.

Correspondence to: Jessica John, Department of Immunology, University of Toronto, Toronto, Canada, E-mail: jessica.john@uni.edu.ca

Received: 21-Apr-2023, Manuscript No. JVV-23-20414; **Editor assigned:** 24-Apr-2023, Pre QC No. JVV-23-20414 (PQ); **Reviewed:** 10-May-2023, QC No JVV-23-20414; **Revised:** 17-May-2023, Manuscript No. JVV-23-20414 (R); **Published:** 25-May-2023, DOI: 10.35248/2157-7560.23.14.529.

Citation: John J (2023) Cancer Vaccines: Approach for Cancer Treatment. J Vaccines Vaccin. 14:529.

Copyright: © 2023 John J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

OPEN ACCESS Freely available online

John J

REFERENCES

- Smeeth L, Rodrigues LC, Hall AJ, Fombonne E, Smith PG. Evaluation of adverse effects of vaccines: the case-control approach. Vaccine. 2002;20(19-20):2611-2617.
- 2. Shrihari T.G. Dual role of inflammatory mediators in cancer. Ecancermedicalscience. 2017;23(11):1-9.
- Kowalczyk DW, Ertl HC. Immune responses to DNA vaccines. Cell Mol Life Sci. 1999;55(5):751-770.
- Jones RG, Liu Y, Rigsby P, Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods. 2008;337(1):42-48.
- 5. Grivennikov S I, Greten F R, Karin M. Immunity, inflammation and cancer. Cell. 2010;140:883-1013.
- Glanben L, Marjorie DF, Peti T, Chanitra T, Marcela AH. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;6:1-20.

- Freddie B, Jacques Ferlay ME, Isabelle S, Rebella LS, Lindsey AT, Ahmedin J. Global cancer statistics 2018: Globocon estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.
- Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine. 1993;11(6):637-642.
- 9. Coussens LM, Werb Z. Inflammation and cancer .Nature 2002;420:860-867.
- Bazin H. A brief history of the prevention of infectious diseases by immunisations. Comp Immunol Microbiol Infect Dis. 2003;26(5-6):293-308.